ICAM1 and cancer: Treatment with anti‐PD‐1 and sICAM‐1 enhanced the anti‐tumor effects in anti‐PD‐1‐sensitive and ‐resistant mouse cancer models, indicating that ICAM‐1 restored anti‐PD‐1 efficacy.